A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Labroots invites you to the 7th Annual Event in the CRISPR Virtual Event Series 2024 taking place on October 23rd, 2024! This event will continue the conversation of the abilities of CRISPR-based ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

The Food and Drug Administration on Friday approved the first drug in the United States to use the revolutionary gene-editing tool called CRISPR-Cas9, a historic action that pushes medicine and ...

the latest shift for a tarantella company that has repeatedly switched direction and leadership since first emerging as one of the first CRISPR biotechs a decade ago. Editas will now focus ...

CRISPR Therapeutics recently proved it was capable of getting a drug approved. Next, its oncology and cardiovascular disease programs will need to show value. It may soon face some financial ...

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms ...

Short interest in CRISPR Therapeutics AG (NASDAQ:CRSP) increased during the last reporting period, rising from 17.56M to 17.59M. This put 23.42% of the company's publicly available shares short.

HG202 is the first CRISPR/Cas13Y RNA-targeting therapy to enter clinical development and the only clinical-stage CRISPR RNA-editing therapy for age-related macular degeneration Preclinical studies ...